Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRVL Prevail Therapeutics (PRVL) Stock Price, News & Analysis Add Share Share Stock Analysis Stock Analysis About Prevail Therapeutics Stock (NASDAQ:PRVL) 30 days 90 days 365 days Advanced Chart Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Prevail Therapeutics alerts:Sign Up Key Stats Today's Range$23.00▼$23.0050-Day Range$22.91▼$23.2052-Week Range$9.02▼$23.35VolumeN/AAverage Volume955,800 shsMarket Capitalization$787.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Read More… Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Receive PRVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRVL Stock News HeadlinesI Prevail + Hollywood Undead SCREAM Through Haunted Blood Prison | Paranormal PrisonNovember 13, 2024 | msn.comHow I Prevail and All Time Low teamed up to create their monster hit “Hate This Song”November 4, 2024 | yahoo.comBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. November 21, 2024 | WealthPress (Ad)Illinois Takes on the Ducks: Will Toughness Prevail?October 25, 2024 | msn.comMedtronic’s Prevail DCB pivotal trial receives FDA IDE approvalOctober 25, 2024 | msn.comSlaughter to Prevail’s Epic New Song ‘Behelit’ Has Fans Reacting to Different StyleOctober 16, 2024 | msn.comLiberty vs. Aces Series Analysis: Who Will Prevail?October 4, 2024 | msn.comHalestorm & I Prevail's ‘Can U See Me in the Dark?' Tops Mainstream Rock Airplay ChartSeptember 25, 2024 | msn.comSee More Headlines PRVL Stock Analysis - Frequently Asked Questions How were Prevail Therapeutics' earnings last quarter? Prevail Therapeutics Inc. (NASDAQ:PRVL) released its quarterly earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.09. When did Prevail Therapeutics IPO? Prevail Therapeutics (PRVL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Prevail Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prevail Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Alector (ALEC), Advanced Micro Devices (AMD), Atreca (BCEL) and Homology Medicines (FIXX). Company Calendar Last Earnings11/13/2020Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRVL CUSIPN/A CIKN/A Webwww.prevailtherapeutics.com Phone917-336-9310FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.57% Return on Assets-48.14% Debt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book4.74Miscellaneous Outstanding Shares34,246,000Free FloatN/AMarket Cap$787.66 million OptionableNot Optionable Beta1.59 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:PRVL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prevail Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prevail Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
